Home > Boards > US OTC > Biotechs > BioVie Inc. (BIVID)

Any progress in the clinical trial schedule should

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
someconcerns Member Profile
 
Followed By 31
Posts 2,561
Boards Moderated 1
Alias Born 04/01/09
160x600 placeholder
someconcerns   Wednesday, 08/14/19 05:45:05 PM
Re: Trend-Setter post# 668
Post # of 744 
Any progress in the clinical trial schedule should be beneficial. There is strength in the markets where there is demand for the drug and it's not directly in the international trade crossfire.

Not allowed to mention the name of the company under IHub TOS, but they put another 9 million shares on the market at $28 today and the share price, rather than dropping from $30 to $28, closed up slightly. This is in TODAYs market. There clearly is demand for their recently approved products and demand for the stock. Of course it is no longer pre-revenue, like BIVI.

DISCLAIMER: All I say is just IMHO and does not constitute investment advice. My wife informs me frequently that I know nothing. I say you should trust no one on the internet.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist